Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose rivaroxaban plus aspirin versus aspirin alone in type 2 diabetes with stable peripheral or carotid artery disease
2019-000610-10Phase 4Completed
- Sponsor
- Policlinico Gemelli
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of rivaroxaban and aspirin in arteriosclerosis obliterans and carotid atheroma (CAS) (2 arms), sponsored by Policlinico Gemelli. Primary endpoint: Urinary 11-dehydro-thromboxane B2 excretion. Started Jun 2021; status: completed.
02
Drugs
rivaroxabanaspirin
03
Conditions
arteriosclerosis obliteranscarotid atheroma (CAS)
Beyond the preview
Go deeper on 2019-000610-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000610-10.